State Street Corp Acquires 50,386 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)

State Street Corp grew its stake in Inozyme Pharma, Inc. (NASDAQ:INZY) by 5.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,050,420 shares of the company’s stock after purchasing an additional 50,386 shares during the period. State Street Corp owned approximately 1.64% of Inozyme Pharma worth $5,494,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of INZY. Bank of New York Mellon Corp boosted its stake in Inozyme Pharma by 16.1% during the second quarter. Bank of New York Mellon Corp now owns 190,896 shares of the company’s stock worth $851,000 after buying an additional 26,464 shares during the period. Rhumbline Advisers boosted its stake in shares of Inozyme Pharma by 22.0% during the 2nd quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock worth $343,000 after purchasing an additional 13,867 shares during the period. American Century Companies Inc. lifted its stake in Inozyme Pharma by 11.0% in the second quarter. American Century Companies Inc. now owns 57,100 shares of the company’s stock worth $255,000 after purchasing an additional 5,673 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Inozyme Pharma during the second quarter valued at approximately $68,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Inozyme Pharma by 117.6% during the second quarter. Dimensional Fund Advisors LP now owns 380,064 shares of the company’s stock valued at $1,695,000 after buying an additional 205,417 shares during the last quarter. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Stock Down 4.3 %

Inozyme Pharma stock opened at $2.92 on Friday. Inozyme Pharma, Inc. has a one year low of $2.38 and a one year high of $7.80. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. The stock has a 50-day moving average of $3.42 and a two-hundred day moving average of $4.51.

Inozyme Pharma (NASDAQ:INZY) last released its earnings results on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. Equities research analysts forecast that Inozyme Pharma, Inc. will post -1.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on INZY. Wedbush reaffirmed an “outperform” rating and issued a $12.00 price objective (down previously from $15.00) on shares of Inozyme Pharma in a research report on Tuesday, November 5th. Stifel Nicolaus initiated coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They set a “buy” rating and a $16.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Inozyme Pharma in a research note on Wednesday, November 6th. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Inozyme Pharma in a report on Wednesday, November 6th. Finally, Raymond James initiated coverage on shares of Inozyme Pharma in a report on Thursday, December 12th. They set an “outperform” rating and a $26.00 target price on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $17.00.

Inozyme Pharma Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.